Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00214773
Status:
COMPLETED
Last Update Posted:
2021-04-05
First Post:
2005-09-13
Brief Title:
Mucopolysaccharidosis MPS VI Clinical Surveillance Program CSP
Sponsor:
BioMarin Pharmaceutical
Organization:
BioMarin Pharmaceutical
Study Overview
Official Title:
MPS VI Clinical Surveillance Program CSP
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this program are to further characterize the natural progression of MPS VI disease to generate and disseminate information on the care and management of MPS VI patients to clinical and medical professionals to provide a resource to physicians and patients by providing information for optimizing patient care based on aggregate data to characterize the clinical response to long-term Naglazyme galsulfase treatment to further characterize the long-term safety of Naglazyme treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None